Quantum BioPharma Ltd C.QNTM

Alternate Symbol(s): QNTM

Healthcare

Quantum BioPharma Ltd. is a Canada-based biopharmaceutical company. The Company is engaged in building a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (Lucid), it is focused on the research and development of its lead compound, Lucid-MS, which is a patented new chemical entity to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. Its unbuzzd beverage is a proprietary formulation of vitamins and minerals to help with liver and brain function for the purposes of relieving the effects of alcohol consumption and restoring a normal lifestyle. It maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.

CSE:QNTM - Post by User

Quantum BioPharma Ltd > Double-Blind Study Takes Time

<< Previous

Bullboard Posts

Next >>

Post by Stockhouse2021on Dec 22, 2020 10:30am

79 Views

Post# 32160328

Double-Blind Study Takes Time

https://www.businesswire.com/news/home/20201215005684/en/FSD-Pharma-Announces-First-Patient-Randomized-in-Phase-2-Trial-of-FSD201-for-the-Treatment-of-Hospitalized-Patients-with-COVID-19

FDA has authorized randomized, controlled, double-blind study on 352 patients. The Company is expected to conduct this trial in 25-30 Medical Centers and Hospitals in North America

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing